Rui Wang, Yuheng Mao, Chunping Yu, Zhenji Rong, Ruyue Wang, Yixin Wang, Linjin Lv, Yang Gao, Zhigang Wang, Hailong Zhang
Nonalcoholic steatohepatitis (NASH), a multi-target disease, is becoming a global epidemic. Although several anti-NASH drug candidates are being evaluated in late-stage clinical trials, none have been approved by the FDA to date. Given the global prevalence of the disease, the lack of effective drugs, and the very limited therapeutic efficacy of most of the existing synthetic drugs focusing on a single target, there is an urgent need to continue to develop new therapeutic agents. In contrast, many natural products, including pure compounds and crude extracts, possess hepatoprotective activities...
May 15, 2024: Mini Reviews in Medicinal Chemistry